Aurinia Announces Results of the 2021 Annual General Meeting

Aurinia Announces Results of the 2021 Annual General Meeting




Aurinia Announces Results of the 2021 Annual General Meeting

VICTORIA, British Columbia–(BUSINESS WIRE)–Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) is pleased to announce that the eight incumbent directors of the Company were elected at the Company’s annual general meeting (the “Meeting”) held on June 7, 2021.

Detailed results of the vote by proxy for the election of directors are provided below:

Nominee

     

Votes For (%)

     

Votes Withheld (%)

George M. Milne

     

80.91

 

 

 

19.09

Peter Greenleaf

     

92.18

 

 

 

7.82

David R.W. Jayne

     

93.00

 

 

 

7.00

Joseph P. Hagan

     

87.15

 

 

 

12.85

Daniel G. Billen

     

95.64

 

 

 

4.36

R. Hector MacKay-Dunn

     

93.27

 

 

 

6.73

Jill Leversage

     

95.05

 

 

 

4.95

Timothy P. Walbert

     

89.56

 

 

 

10.44

In addition, following final tallies of votes, all other matters voted on at the Meeting were also approved. Voting results on all matters voted on at the Meeting will be filed on SEDAR at www.sedar.com and EDGAR at www.edgar.com.

About Aurinia

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.

Contacts

Investors:
Glenn Schulman, PharmD, MPH

Investor Relations & Corporate Communications, Aurinia

gschulman@auriniapharma.com

Media:
Dana Lynch

Corporate Communications, Aurinia

dlynch@auriniapharma.com